# Bristol Myers Squibb Says KarXT Improved Alzheimer’s Psychosis Scores

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/60670
Published: 2026-11-18T17:22:48.000Z
Updated: 2026-11-18T17:22:48.000Z
Section: Business

> The two Phase 3 trials found gains in hallucination and delusion scores, and the xanomeline and trospium chloride treatment was well tolerated.

Bristol Myers Squibb said results from two Phase 3 trials of KarXT showed improved scores for hallucinations and delusions associated with Alzheimer’s disease psychosis.

The company said KarXT, which contains xanomeline and trospium chloride, was well tolerated in the trials.


